Hematology analyzers are automated systems designed to count leucocytes, platelets, and red cells in the blood. The technology in hematology analyzers has evolved at a rapid pace over a very short period. Currently, hematology analyzers can determine the level of hemoglobin and hematocrit. Earlier, complete blood count (CBC) was examined manually by laboratory technicians which involved human errors. However, with the advent of hematology analyzers, healthcare professionals could get accurate results in a short period. The feature of programmable automated alarm systems in hematology analyzers increased their demand drastically. Currently, these devices are used to detect and monitor diseases. The rise in the number of patients suffering from blood cancer, blood clots, and hemophilia has increased the demand for hematology analyzers.
According to Allied Market Research, the global hematology analyzer market is expected to reach $3.94 billion by 2030, growing at a CAGR of 7.3% from 2021 to 2030. Rise in the prevalence of blood disorders and growth in demand for automated hematology analyzers along with surge in inclination toward high sensitivity hematology analyzers have boosted the growth of the market growth. In addition, the rapid technological advancements in hematology analyzers supplement the market growth. The rapid launch of the novel, technologically advanced hematology analyzers has unlocked new opportunities.
Technological developments, increase in demand for automated hematology analyzers, and rise in preference toward high sensitivity hematology analyzers are the factors that drive the global hematology analyzer market. On the other hand, high cost of hematology analyzers due to advanced features and automation and strict regulatory policies hinder the market growth.
IDEXX Laboratories, Inc., a leading company in veterinary diagnostics and software, launched ProCyte One Hematology Analyzer to maintain workflow simplicity and consistency and offer accurate results at the point of care. The hematology analyzer includes simple workflow and virtually eliminates complexity without compromising the performance and accuracy of results. Similar to IDEXX, many companies have invested in development of hematology analyzers, especially in how to integrate automation in the device.
Currently, there are a few jobs where clinicians are mandatory such as transferring blood samples from the collecting tube to the instrument. However, in the future, hematology analyzers would limit human involvement as much as possible to eliminate the risk of aerosols released while collecting the tube. The device operator merely needs to place the caped collection tube in the sample carrier and it will automatically enter the device for analysis. With the advent of the Internet of Things (IoT), these devices will receive major upgrades. The healthcare professionals would receive the reports and updates promptly on a regular basis. The advent of new technologies would make hematology analyzers safer, more accurate, and much easier to handle.
Impact of COVID-19 Pandemic on the Hematology Analyzer Market
COVID-19 is a large family of viruses that causes illness ranging from common cold to more severe respiratory diseases. The COVID-19 pandemic has helped the industry grow significantly, as the demand for hematology analyzer increased owing to increase in focus on the hematology parameters for the assessment of COVID-19 around the world. This supports the hematology analyzer market to gain traction during the forecast period.
- A few subdomains of healthcare industry had to pause or shut their operations due to lockdown and lack of workforce.
- The pandemic affected the hematology analyzer market positively, attributing to an increase in focus on the hematology parameters to assess the COVID-19 infection.
No comments:
Post a Comment